Cargando…

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1

Detalles Bibliográficos
Autores principales:	Sosenko, Jay M., Skyler, Jay S., Herold, Kevan C., Palmer, Jerry P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Perspectives in Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357303/ https://www.ncbi.nlm.nih.gov/pubmed/22618768 http://dx.doi.org/10.2337/db11-1660

Ejemplares similares

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
por: Skyler, Jay S., et al.
Publicado: (2011)

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Sosenko, Jay M., et al.
Publicado: (2010)

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2008)

β-Cell Mass and Type 1 Diabetes: Going, Going, Gone?
por: Akirav, Eitan, et al.
Publicado: (2008)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2010)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
por: Skyler, Jay S., et al.
Publicado: (2017)

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2014)

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Orban, Tihamer, et al.
Publicado: (2009)

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2009)

How Does Type 1 Diabetes Develop?: The Notion of Homicide or β-Cell Suicide Revisited
por: Atkinson, Mark A., et al.
Publicado: (2011)

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
por: Ferrannini, Ele, et al.
Publicado: (2010)

A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 (DPT-1) Participants
por: Sosenko, Jay M., et al.
Publicado: (2011)

A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History
por: Sosenko, Jay M., et al.
Publicado: (2015)

Type 1 Diabetes at a Crossroads!
por: Cefalu, William T., et al.
Publicado: (2015)

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
por: Sosenko, Jay M., et al.
Publicado: (2013)

Hypoglycemia in Type 1 Diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2010)

The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2012)

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes
por: Sims, Emily K., et al.
Publicado: (2021)

The Streetlight Effect in Type 1 Diabetes
por: Battaglia, Manuela, et al.
Publicado: (2015)

Oral tolerance therapy in type 1 diabetes mellitus
por: Mao, Rui-Feng, et al.
Publicado: (2021)

Genetics of Type 1 Diabetes: What's Next?
por: Pociot, Flemming, et al.
Publicado: (2010)

Viral Trigger for Type 1 Diabetes: Pros and Cons
por: Filippi, Christophe M., et al.
Publicado: (2008)

Central Role for Interleukin-2 in Type 1 Diabetes
por: Hulme, Maigan A., et al.
Publicado: (2012)

Antigen-Based Therapy for the Treatment of Type 1 Diabetes
por: Tian, Jide, et al.
Publicado: (2009)

Uncovering Pathways to Personalized Therapies in Type 1 Diabetes
por: Linsley, Peter S., et al.
Publicado: (2021)

Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes
por: Sellmeyer, Deborah E., et al.
Publicado: (2016)

The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes
por: Wahren, John, et al.
Publicado: (2012)

Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential
por: Peakman, Mark, et al.
Publicado: (2010)

The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes
por: Purcell, Anthony W., et al.
Publicado: (2019)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
por: Palmer, Allyson K., et al.
Publicado: (2015)

It’s Time to Bring Dendritic Cell Therapy to Type 1 Diabetes
por: Creusot, Rémi J., et al.
Publicado: (2014)

Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance
por: Moon, Hyun-Seuk, et al.
Publicado: (2011)

Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2010)

Posttranslational Modifications of Proteins in Type 1 Diabetes: The Next Step in Finding the Cure?
por: Dunne, Jessica L., et al.
Publicado: (2012)

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011)

Immunomodulation by Mesenchymal Stem Cells : A Potential Therapeutic Strategy for Type 1 Diabetes
por: Abdi, Reza, et al.
Publicado: (2008)

From Pancreatic β-Cell Gene Networks to Novel Therapies for Type 1 Diabetes
por: Eizirik, Decio L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4psjk3u72788la321su2m4qp4h